RUNX1 and uterine cancer: In addition, deep deletion of RUNX1 occurred in 6.59% (12 cases) of patients with ESCA (182 cases), and mutations in RUNX1 were the primary alteration type in 4.91% (26 cases) of patients with uterine cancer (529 cases).